Does a Methicillin-resistant Staphylococcus aureus (MRSA) nasal swab correlate with an active MRSA infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A positive MRSA nasal swab does not necessarily correlate with active infection, as it detects colonization rather than disease. When considering the relationship between MRSA nasal swabs and active infection, it's essential to understand that colonization and infection are distinct concepts. Colonization refers to the presence of the bacteria in the nose without causing disease, whereas infection implies the presence of clinical signs such as redness, swelling, warmth, pain, and purulent drainage, along with positive cultures from the infected site 1.

Key Considerations

  • The likelihood of MRSA colonization increases with prior history of MRSA infection, hospitalization, receipt of antibiotics, or presence of select comorbid conditions, such as immunosuppression, diabetes, and chronic obstructive pulmonary disease 1.
  • Surgical patients identified as colonized with MRSA have been found to have 2-fold to 14-fold greater odds of a subsequent MRSA surgical site infection (SSI) than patients with negative nasal MRSA screens 1.
  • Decolonization protocols, including the use of mupirocin nasal ointment and chlorhexidine body washes, may be considered for patients with positive nasal swabs but no symptoms, especially before certain surgeries or in high-risk settings.

Clinical Implications

  • Healthcare providers should evaluate clinical presentation alongside laboratory results when determining if treatment is necessary.
  • The distinction between colonization and infection is crucial because colonization alone typically doesn't require systemic antibiotics, while active infections do.
  • Nasal screening for MRSA can help identify individuals at higher risk of developing active infections, particularly in healthcare settings or during invasive procedures 1.

Management Approach

  • For patients with positive nasal swabs but no symptoms, decolonization might be considered using mupirocin nasal ointment (2% applied to each nostril twice daily for 5 days) and chlorhexidine body washes.
  • This approach is particularly important before certain surgeries or in high-risk settings, where the risk of developing active MRSA infections is higher.

From the Research

MRSA Nasal Swab Correlation with Active Infection

  • The correlation between MRSA nasal swab results and active infection is a topic of interest in the medical field, with several studies investigating this relationship 2.
  • A study published in 2017 found that nasal-swab screening for MRSA had a sensitivity of 58.3% and a specificity of 93.9% in predicting MRSA infections in hospitalized patients 2.
  • The same study found that a positive nasal swab result significantly increased the likelihood of MRSA infection, while a negative result significantly reduced the probability of MRSA infection 2.
  • Another study published in 2021 found that linezolid was superior to vancomycin in improving clinical and microbiological success in treating patients with suspected or proven complicated skin and soft tissue infections caused by MRSA 3.
  • However, it is essential to note that the correlation between MRSA nasal swab results and active infection may vary depending on the specific context and population being studied.
  • The use of MRSA nasal swab results to guide antimicrobial therapy is not universally recommended, and clinicians should consider the results in conjunction with other clinical and laboratory findings 2, 4.

Diagnostic Characteristics of Nasal-Swab Screening

  • The diagnostic characteristics of nasal-swab screening for MRSA include:
    • Sensitivity: 58.3% (95% CI 28.6%-83.5%) 2
    • Specificity: 93.9% (95% CI 90.0%-96.3%) 2
    • Positive predictive value: 30.4% (95% CI 14.1%-53.0%) 2
    • Negative predictive value: 98.0% (95% CI 95.1%-99.3%) 2
    • Positive likelihood ratio: 9.5 (95% CI 4.9-18.7) 2
    • Negative likelihood ratio: 0.4 (95% CI 0.2-0.9) 2

Treatment Options for MRSA Infections

  • Treatment options for MRSA infections include vancomycin, daptomycin, linezolid, and combination therapies 5, 6, 3, 4.
  • The choice of treatment depends on various factors, including the severity of the infection, the patient's medical history, and the susceptibility of the MRSA strain to different antibiotics.
  • Clinicians should consider the latest evidence and guidelines when selecting treatment options for MRSA infections 5, 6, 3, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.